TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03500263

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PTI-808
Description: Active

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PTI-808
Description: Active

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PTI-808
Description: Active

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PTI-801
Description: Active

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PTI-801
Description: Active

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PTI-801
Description: Active

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PTI-428
Description: Active

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PTI-428
Description: Active
Study: NCT04600063

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Isolation procedure (RAMPS procedure)
Description: In the Isolation procedure group, the transection of the root of the splenic artery and the pancreatic transection are performed first, followed by the transection of the splenic vein (mandatory procedure). At that time, the branch from the splenic artery (dorsal pancreatic artery), the branch to the splenic vein (left gastric vein, inferior mesenteric vein), and short gastric arteriovenous are also disconnected as soon as possible (recommended procedure). An operation to lift up the pancreatic neck from the dorsal portal vein or superior mesenteric artery to expose the splenic vein (so-called tunneling) is allowed. After that, lymph node dissection such as hepatoduodenal mesentery (No12), common hepatic artery perimeter (No8), lymph node dissection around SMA (No14p) was performed (recommended procedure), and at the end of the resection operation, the pancreas body/tail and spleen are mobilized and removed (required procedure).
Study: NCT03500263

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03424525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-Trimethoprim
Description: \[11C\]TMP is a radiolabeled imaging agent for positron emission tomography (PET/CT). Most relevant to this protocol, it is for imaging bacterial infection in human subjects. TMP is well-known, safe, broad-spectrum, synthetic, small molecule antibiotic that has been used clinically for over 50 years for the treatment of acute bacterial infection and has been combined with sulfa-based antibiotics (Bactrim/Septra) for bacterial infection prophylaxis especially in the lung and bladder.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-Trimethoprim
Description: \[11C\]TMP is a radiolabeled imaging agent for positron emission tomography (PET/CT). Most relevant to this protocol, it is for imaging bacterial infection in human subjects. TMP is well-known, safe, broad-spectrum, synthetic, small molecule antibiotic that has been used clinically for over 50 years for the treatment of acute bacterial infection and has been combined with sulfa-based antibiotics (Bactrim/Septra) for bacterial infection prophylaxis especially in the lung and bladder.
Study: NCT02762539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omega-3 enriched SMOF lipid emusion
Study: NCT03646695

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ILM flap transposition
Description: during ILM flap Transposition, an ILM flap is placed on the macular hole

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ILM peeling
Description: during ILM Peeling the ILM is removed around the macular hole
Study: NCT02652377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-494
Description: 10, 100 and 200 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-494
Description: 10, 100 and 200 mg capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo to match EDP-494

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo to match EDP-494
Study: NCT03209050

Intervention type: DEVICE
Group type: OTHER
Intervention: Central Venous Access Placement
Description: Device inserted into the femoral vein to insert a central venous access catheter
Study: NCT02470611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium alendronate
Description: After manual quadrant-wise scaling and root planing, at the final treatment appointment the randomized selected periodontal site (showing pocket depth ≥ 5mm, clinical attachment loss \> 3mm and proximal bone defects) received 1% sodium alendronate gel

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After manual quadrant-wise scaling and root planing, at the final treatment appointment the randomized selected periodontal site (showing pocket depth ≥ 5mm, clinical attachment loss \> 3mm and proximal bone defects) received 1% placebo gel
Study: NCT01414556

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose-dependent Insulinotropic polypeptide
Description: infusion 4 pmol x kg x min first 15 min, thereafter 2 pmol x kg x min

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose-dependent Insulinotropic polypeptide
Description: infusion 4 pmol x kg x min first 15 min, thereafter 2 pmol x kg x min

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose-dependent Insulinotropic polypeptide
Description: infusion 4 pmol x kg x min first 15 min, thereafter 2 pmol x kg x min

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: saline

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: saline

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: saline
Study: NCT00570557

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TOR-BSST© Refresher Training
Description: Web-based refresher training in dysphagia screening
Study: NCT02316847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diazepam nasal spray

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diazepam nasal spray
Study: NCT02494752

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fat graft enriched with ex vivo expanded stem cells
Description: Fat graft will be enriched with ex vivo expanded stem cells

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fat graft not enriched with ex vivo expanded stem cells
Description: Fat graft will not be enriched with ex vivo expanded stem cells
Study: NCT01265121

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous positive air pressure device (CPAP)
Description: After titrating the air pressure during a polysomnography test, a CPAP device will be applied to the patient, during the night, for three months.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: External nasal dilator adhesive
Description: An external nasal dilator adhesive will be given to patients. They will be applied on the nose and will be used for three months aiming to serve as a placebo for snoring and sleep apnea.
Study: NCT04225039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCMGA00012
Description: 500mg IV neoadjuvant treatment; 500 mg adjuvant treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCMGA00012
Description: 500mg IV neoadjuvant treatment; 500 mg adjuvant treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCMGA00012
Description: 500mg IV neoadjuvant treatment; 500 mg adjuvant treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCAGN01876
Description: 300mg IV neoadjuvant treatment; 300 mg adjuvant treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCAGN01876
Description: 300mg IV neoadjuvant treatment; 300 mg adjuvant treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCAGN01876
Description: 300mg IV neoadjuvant treatment; 300 mg adjuvant treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SRS
Description: administered over the course of 3 consecutive business days (8 Gy x 3 fractions, one fraction per day, total dose 24 Gy).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SRS
Description: administered over the course of 3 consecutive business days (8 Gy x 3 fractions, one fraction per day, total dose 24 Gy).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brain surgery
Description: maximal safe surgical resection of the tumor.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brain surgery
Description: maximal safe surgical resection of the tumor.
Study: NCT04335370

Intervention type: OTHER
Intervention: Blood Draw
Description: Blood samples will be collected from enrolled patients at 5 time points during a single dosing interval:~1. Prior to start of infusion~2. End of infusion~3. One hour after end of infusion~4. Three hours after end of infusion~5. Eight hours after start of infusion
Study: NCT02127489

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1 mL/kg bupivacaine 0.25%.
Description: 40 children between 2 and 10 years of ASA I-II were randomized and they received caudal anesthesia under general anesthesia. Patients underwent the application of caudal block in addition with saline and 1 mL/kg bupivacaine 0.25%. In the postoperative period, Group C (n=20) was given 5mL saline and Group M (n=20) was given 0.30 mg/kg rectal midazolam diluted with 5mL saline. Sedation scale and postoperative pain scale (CHIPPS) of the patients were evaluated. The patients were observed for their analgesic need, first analgesic time, and adverse effects for 24 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 1 mL/kg bupivacaine 0.25%.
Description: 40 children between 2 and 10 years of ASA I-II were randomized and they received caudal anesthesia under general anesthesia. Patients underwent the application of caudal block in addition with saline and 1 mL/kg bupivacaine 0.25%. In the postoperative period, Group C (n=20) was given 5mL saline and Group M (n=20) was given 0.30 mg/kg rectal midazolam diluted with 5mL saline. Sedation scale and postoperative pain scale (CHIPPS) of the patients were evaluated. The patients were observed for their analgesic need, first analgesic time, and adverse effects for 24 hours.
Study: NCT03497780

Intervention type: PROCEDURE
Intervention: Anterior cruciate ligament reconstruction
Description: Primary surgical reconstruction of the rupture anterior cruciate ligament
Study: NCT02975297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Exenatide Injectable Product will be administered at a dose of 2 mg subcutaneously once a week for 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRT
Description: Nicotine Patch (21mg) / 24 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NRT
Description: Nicotine Patch (21mg) / 24 hours.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Brief individual behavioral smoking cessation counseling.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Counseling
Description: Brief individual behavioral smoking cessation counseling.
Study: NCT04600063

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Conventional procedure
Description: In the conventional procedure group, first, the pancreatic body and tail and spleen are mobilized (mandatory procedure), and the regional lymph nodes of the body and tail of the pancreas, such as the hepatoduodenal mesentery (No12 lymph node) and the common hepatic artery perimeter (No8), are removed. (Recommended procedure) and dissection of lymph nodes (No14p) around SMA (Recommended procedure), and after dissection of the gastro-splenic ligament and pancreas, transection of the splenic vein at the end of the resection procedure (required procedure) . However, in order to prevent bleeding and secure a safe field of view, early pancreatotomy is allowed.
Study: NCT02975297

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline.
Study: NCT02945007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-53718678
Description: Participants will receive JNJ-53718678 under fed or fasted conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-53718678
Description: Participants will receive JNJ-53718678 under fed or fasted conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-53718678
Description: Participants will receive JNJ-53718678 under fed or fasted conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-53718678
Description: Participants will receive JNJ-53718678 under fed or fasted conditions.
Study: NCT04600063

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional procedure
Description: In the conventional procedure group, first, the pancreatic body and tail and spleen are mobilized (mandatory procedure), and the regional lymph nodes of the body and tail of the pancreas, such as the hepatoduodenal mesentery (No12 lymph node) and the common hepatic artery perimeter (No8), are removed. (Recommended procedure) and dissection of lymph nodes (No14p) around SMA (Recommended procedure), and after dissection of the gastro-splenic ligament and pancreas, transection of the splenic vein at the end of the resection procedure (required procedure) . However, in order to prevent bleeding and secure a safe field of view, early pancreatotomy is allowed.
Study: NCT00667186

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Targeted Screening
Description: Selection method for screening is based on risk

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Screening
Description: Selection method for screening is not based on risk
Study: NCT00980174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 60 mg denosumab
Description: 60 mg denosumab (SC injection every 6 months)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 60 mg denosumab
Description: 60 mg denosumab (SC injection every 6 months)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for denosumab (SC injection every 6 months)
Study: NCT02747797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucitanib
Description: 10 mg orally daily
Study: NCT04588727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3366
Description: In Part A, subjects will be randomized to receive intravenous infusion AZD3366 dose 1-7, single ascending dose (SAD). In Part A, Dose 2-7 may be adjusted based on PK data from previous cohort\[s\]. In Part B, subjects will be randomized to receive intravenous infusion AZD3366 dose X (a dose resulting in predicted therapeutic exposure).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3366
Description: In Part A, subjects will be randomized to receive intravenous infusion AZD3366 dose 1-7, single ascending dose (SAD). In Part A, Dose 2-7 may be adjusted based on PK data from previous cohort\[s\]. In Part B, subjects will be randomized to receive intravenous infusion AZD3366 dose X (a dose resulting in predicted therapeutic exposure).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3366
Description: In Part A, subjects will be randomized to receive intravenous infusion AZD3366 dose 1-7, single ascending dose (SAD). In Part A, Dose 2-7 may be adjusted based on PK data from previous cohort\[s\]. In Part B, subjects will be randomized to receive intravenous infusion AZD3366 dose X (a dose resulting in predicted therapeutic exposure).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3366
Description: In Part A, subjects will be randomized to receive intravenous infusion AZD3366 dose 1-7, single ascending dose (SAD). In Part A, Dose 2-7 may be adjusted based on PK data from previous cohort\[s\]. In Part B, subjects will be randomized to receive intravenous infusion AZD3366 dose X (a dose resulting in predicted therapeutic exposure).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3366
Description: In Part A, subjects will be randomized to receive intravenous infusion AZD3366 dose 1-7, single ascending dose (SAD). In Part A, Dose 2-7 may be adjusted based on PK data from previous cohort\[s\]. In Part B, subjects will be randomized to receive intravenous infusion AZD3366 dose X (a dose resulting in predicted therapeutic exposure).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3366
Description: In Part A, subjects will be randomized to receive intravenous infusion AZD3366 dose 1-7, single ascending dose (SAD). In Part A, Dose 2-7 may be adjusted based on PK data from previous cohort\[s\]. In Part B, subjects will be randomized to receive intravenous infusion AZD3366 dose X (a dose resulting in predicted therapeutic exposure).
Study: NCT05927506

Intervention type: BEHAVIORAL
Intervention: Other
Description: Observational study of behavior cognitive and motor control

Intervention type: BEHAVIORAL
Intervention: Other
Description: Observational study of behavior cognitive and motor control
Study: NCT03772041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-61815
Description: Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 16 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolvaptan Tab 15 MG
Description: Once daily for 5 days tolvaptan 15-mg tablet will be orally administered, followed immediately by 1-hour intravenous administration of placebo
Study: NCT02271685

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instructions about Overestimates
Description: Participants are told that overestimating the duration of sounds are associated with low disease risk.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instructions about Overestimates
Description: Participants are told that overestimating the duration of sounds are associated with low disease risk.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instructions about Parkinson's
Description: Participants are told that the task is about risk of Parkinson's disease.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instructions about Parkinson's
Description: Participants are told that the task is about risk of Parkinson's disease.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instructions about Underestimates
Description: Participants are told that underestimating the duration of sounds are associated with low disease risk.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instructions about Underestimates
Description: Participants are told that underestimating the duration of sounds are associated with low disease risk.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instructions about Alzheimers
Description: Participants are told that the task is about risk of Alzheimers disease.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instructions about Alzheimers
Description: Participants are told that the task is about risk of Alzheimers disease.
Study: NCT00703105

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC vaccination
Description: DC vaccination with 1 x 10(6th) tumor lysate or tumor peptides and KLH-loaded immature DCs into inguinal nodes identified by ultrasound guidance for a total of three injections at two week intervals; (6 weeks)
Study: NCT03371485

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AST-VAC2
Description: Allogeneic dendritic cell vaccine.
Study: NCT02723305

Intervention type: OTHER
Intervention: No intervention

Intervention type: OTHER
Intervention: No intervention
Study: NCT04061863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 360mg on D1 every 3 weeks Eribulin 1.4mg/m2 on D1, 8 every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 360mg on D1 every 3 weeks Eribulin 1.4mg/m2 on D1, 8 every 3 weeks
Study: NCT02737202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saracatinib
Description: Subjects will receive enough tablets for 90 days +/- 14 days at each visit. Subject will have visits every 90 days for drug accountability as well as safety and efficacy testing to include pulmonary function testing, laboratory testing to include liver and kidney profile, urine pregnancy testing at each visit, vital signs, physical examination - any medically significant changes from baseline visit will be recorded, all adverse events will be monitored until resolution.
Study: NCT02236598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K+ supplement

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT03140449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Description: topical rapamycin (0.1%) or calcitriol (3 mcg/g) single-agent therapy versus their combination were applied twice a day by a left-right randomized, split-face comparison for 12 weeks.~In period 2, the patients entered an open-label study and were reassigned to use the more effective ointment on both cheeks for another 12 weeks (week 13-24).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol
Description: topical rapamycin (0.1%) or calcitriol (3 mcg/g) single-agent therapy versus their combination were applied twice a day by a left-right randomized, split-face comparison for 12 weeks.~In period 2, the patients entered an open-label study and were reassigned to use the more effective ointment on both cheeks for another 12 weeks (week 13-24).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin-calcitriol combination
Description: topical rapamycin (0.1%) or calcitriol (3 mcg/g) single-agent therapy versus their combination were applied twice a day by a left-right randomized, split-face comparison for 12 weeks.~In period 2, the patients entered an open-label study and were reassigned to use the more effective ointment on both cheeks for another 12 weeks (week 13-24).